lilly zepbound weight loss - Search News

Eli Lilly, drugs and weight loss

YAHOO!Finance · 1h

Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. Eli Lilly now expects revenue to be approximately $13.

Hosted on MSN · 2d

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

MarketWatch on MSN · 3d

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

High-dose Wegovy leads to substantial weight loss in trial

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

FierceBiotech · 4d

Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes can muscle in on the market. Kailera and partner Jiangsu Hengrui Pharmaceuticals linked the injectable GLP-1/GIP receptor dual agonist to 22.8% mean weight loss after 36 weeks.

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

20h

Websites selling compounded weight-loss drugs fail to inform patients of risks, research shows

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

6d

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

8don MSN

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

9don MSN

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

3d

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

2don MSN

As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results